Clinical trials: Asymptomatic Brain Metastases
Lung Cancer
Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)
NSCLC patients often have cerebral metastasis : 10% at diagnosis and 40% during disease management. Neurosurgery is not indicated in the majority of cases because of presence of several lesions in the brain, failure of primary…
- Trial name
- GFPC 07-01 (NCT00744900)
- Testing
- Pemetrexed, cisplatin
- Where
- 25 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Brain Metastases
The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC
Brain metastasis is the most common neurological complication in tumor patients, and lung cancer is the most common tumor with brain metastasis.
- Trial name
- BRATR (NCT04193007)
- Testing
- molecular targeted therapies, Brain Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Nonsmall Cell Lung Cancer
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
The need of radiosurgery is controversial for asymptomatic oligo brain metastasis for non small cell lung cancer (NSCLC). Therefore, the investigators do a randomized study comparing overall survival between two groups with or…
- Trial name
- NCT01301560
- Testing
- Radiosurgery, Observation
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer Stage IV
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM.
- Trial name
- ATEZO-BRAIN (NCT03526900)
- Testing
- Atezolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Lung Cancer Group
Lung Cancer
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
The goal of this clinical research study is to learn how effective the drug pemetrexed (ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS) (inability to perform every day activities without…
- Trial name
- NCT00508144
- Testing
- Alimta
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Melanoma
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs.
- Trial name
- USZ-STRIKE (NCT05522660)
- Testing
- Stereotactic radiosurgery, Immune checkpoint inhibitor
- Where
- 15 sites in Italy, Netherlands and 3 more
- Volunteers
- 180 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-Small Cell Lung Cancer, Brain Metastases
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was benefitted by first line chemotherapy.
- Trial name
- NCT00663689
- Testing
- erlotinib
- Volunteers
- 45 people
- Sponsor
- Guangdong Provincial People's Hospital
Melanoma, Brain Metastases
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.
- Trial name
- NCT06712927
- Testing
- Ipilimumab, Nivolumab + Relatlimab FDC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
The purpose of this study is to determine whether EGFR-TKI can control the development of intracranial lesions in Non Small Cell Lung Cancer patients with asymptomatic brain metastases, and the difference in progression free…
- Trial name
- EABM (NCT02250846)
- Testing
- EGFR-TKI
- Volunteers
- 70 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NSCLC Stage IV, Brain Metastases, Adult
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease…
- Trial name
- NCT06401824
- Testing
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht University Medical Center
Non Small Cell Lung Cancer
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally.
- Trial name
- NCT07234877
- Testing
- Ivonescimab, Carboplatin, Pemetrexed
- Where
- 26 sites in Austria, France and 6 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2 Positive Breast Cancer
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma.
- Trial name
- HER2CLIMB (NCT02614794)
- Testing
- tucatinib, capecitabine, trastuzumab
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 612 people
- Sponsor
- Seagen Inc.
Non-small Cell Lung Cancer
Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)
The prognosis of NSCLC patients with asymptomatic brain metastasis, who are not treated with SRS or WBRT has not been fully investigated yet.
- Trial name
- NCT01130766
- Testing
- stereotactic radiosurgery (SRS)
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
This study will assess the efficacy and safety of Avastin combined with first li ne paclitaxel-carboplatin (cohort 1) or second line Tarceva (cohort 2) in patien ts with non-squamous non-small cell lung cancer with asymptomatic…
- Trial name
- NCT00800202
- Testing
- bevacizumab [Avastin], carboplatin, erlotinib [Tarceva]
- Where
- 25 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
This is an open-label, single-intervention, multicenter clinical trial in patients with non-small cell lung cancer with asymptomatic or mildly symptomatic brain metastases after failure of EGFR TKI treatment.
- Trial name
- NCT05326425
- Testing
- lazertinib(YH25448)
- Where
- 6 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Jin Hyoung Kang
Small-cell Lung Cancer, Brain Metastases
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
This is a single arm, multicenter phase II trial for 60 patients with untreated extensive stage (ES) small cell lung cancer (SCLC) with asymptomatic brain metastases.
- Trial name
- NCT04610684
- Testing
- Carboplatin, Etoposide, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Jeffrey Clarke
Lung Cancer, NSCLC
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily.
- Conditions
- Lung Cancer, NSCLC, Brain Metastases
- Trial name
- DURABLE (NCT05987644)
- Testing
- Alectinib, Stereotactic Radiosurgery
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Joshua Palmer
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center